SEC Comment Letter for VERTEX PHARMACEUTICALS (VRTX) — Feb 17, 2017
VERTEX PHARMACEUTICALS INC / MA (VRTX) (CIK 0000875320)
Date: Feb. 17, 2017 · CIK: 0000875320 · Accession: 0000000000-17-005684
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 000-19319
Letter
Mail Stop 4546 February 17, 2017 VIA E -mail Dr. Jeffrey M. Leiden , M.D., Ph.D. Chairman of the Board, Presid ent and Chief Executive Officer Vertex Pharmaceuticals Incorporated 50 Northern Avenue , Boston, Massachusetts 02210
Re: Vertex Pharmaceuticals Incorporated Form 10-K for Fis cal Year Ended December 31, 2015 Filed February 16 , 2016 File No. 000-19319
Dear Dr. Leiden :
We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Sincerely,
/s/ Sharon M. Blume
Show Raw Text
Mail Stop 4546 February 17, 2017 VIA E -mail Dr. Jeffrey M. Leiden , M.D., Ph.D. Chairman of the Board, Presid ent and Chief Executive Officer Vertex Pharmaceuticals Incorporated 50 Northern Avenue , Boston, Massachusetts 02210 Re: Vertex Pharmaceuticals Incorporated Form 10-K for Fis cal Year Ended December 31, 2015 Filed February 16 , 2016 File No. 000-19319 Dear Dr. Leiden : We have completed our review of your filing. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Sincerely, /s/ Sharon M. Blume Sharon M. Blume Accounting Branch Chief Office of Healthcare and Insurance